Elvina Almuradova/LinkedIn
Apr 10, 2025, 17:20
Elvina Almuradova: Evolving HER2 Testing in the ADC Era
Elvina Almuradova, Ambassador at European School of Oncology, shared on LinkedIn:
“Evolving HER2 Testing in the ADC Era!
New HER2-targeted ADCs (like trastuzumab deruxtecan) work even in HER2-low tumors – challenging current diagnostic standards.
Key points:
- Traditional IHC/FISH may miss HER2-low cases
- Quantitative immunofluorescence and RNA-based assays offer more precision
- Standardized, sensitive tests are needed across all solid tumors
- Accurate HER2 assessment is now essential for personalized therapy”
See article related to ADCs on OncoDaily:
Bladder Cancer Treatment: The Game-Changing Role of Antibody-Drug Conjugates (ADCs)
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 02:27
Apr 19, 2025, 22:24
Apr 19, 2025, 22:03
Apr 19, 2025, 21:39
Apr 19, 2025, 21:21
Apr 19, 2025, 21:04
Apr 19, 2025, 20:48
Apr 19, 2025, 20:25
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17